Logo Image
Feature|Podcasts|July 20, 2026

Hiring and Fostering Top Talent

Nuvation CEO David Hung discusses his leadership style, success stories for building camaraderie, and his inspiration for joining the pharma and biotech industry.

David Hung, president, CEO, and founder of Nuvation Bio, discusses his leadership style, emphasizing the importance of hiring top talent and fostering a strong company culture. He draws parallels between elite military teams and biotech teams, highlighting the need for bonding and cross-functional interaction. He then advises young biotech professionals to be objective with data and stressed the importance of a motivating, collegial culture.

  • He emphasizes the importance of making clear, best decisions for the company, which can affect many people, including patients.
  • The patient's death during medical oncology fellowship led David to decide he did not want to spend his career administering outdated treatments like chemotherapy.
  • David compares a biotech company to an organism, stressing the importance of cross-functional interaction and a cohesive team to achieve success.
  • David emphasizes the importance of company culture, drawing parallels between elite military teams and biotech teams, highlighting the need for bonding and connection among team members.

Related to this article

View more
Pharmaceutical Executive daily
Pharmaceutical Executive Daily: Peptide Ruling Stalls
Novo Nordisk data show real-world weight loss after switching to its oral semaglutide pill, FDA's peptide rulemaking stalls while its enforcement arm targets compounded peptide sellers, and Avi Pardo flags a compliance blind spot in field teams' text messages with doctors.
Read more
Pharmaceutical Executive daily
Pharmaceutical Executive Daily: FDA Approves Welireg Plus Lenvima
FDA approves Merck and Eisai's Welireg-Lenvima combination for advanced kidney cancer, a platform-deal roundup covers Novo Nordisk, Genentech, and Roche's tie-ups with Nanexa, Earendil Labs, and Atavistik Bio, and Ron Lanton examines the fight to regulate pharmacy benefit managers.
Read more
Pharmaceutical executive daily
Pharmaceutical Executive Daily: FDA Approves Onswik
InnoCare Pharma and Eli Lilly ink a multibillion-dollar research collaboration, FDA approves Lilly's once-weekly insulin Onswik for type 2 diabetes, and Jen Lamppa talks fixing clinical trial patient enrollment with real-world data.
Read more